|
2023-24 Evaluation_Internal Medicine Endocrinology Journal Club & Trial Tumor Board |
07/01/2023 - 6:00am EDT to 06/30/2024 - 5:00pm EDT |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism" |
07/11/2023 - 7:00am to 8:00am EDT |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Cardiovascular Safety of Testosterone-Replacement Therapy" |
08/08/2023 - 7:00am to 8:00am EDT |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 |
09/12/2023 - 7:00am to 8:00am EDT |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "AGA Clinical Practice Update on the Role of Noninvasive" |
10/10/2023 - 7:00am to 8:00am EDT |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Tumor Board" |
11/14/2023 - 7:00am to 8:00am EST |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Triple–Hormone-Receptor Agonist" |
12/12/2023 - 7:00am to 8:00am EST |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Retatrutide for Obesity — A Phase 2 Trial" |
01/09/2024 - 7:00am to 8:00am EST |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Approaching Primary Aldosteronism as a Common Disease" |
02/13/2024 - 7:00am to 8:00am EST |
|
Internal Medicine Endocrinology Journal Club & Trial Tumor Board 2023-24 "Tumor Board" |
03/12/2024 - 7:00am to 8:00am EDT |
Facebook
Twitter
LinkedIn
Forward